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Abstract Matrix metalloproteinases (MMPs) are zinc-
dependent endopeptidases, responsible for the integrity of
the basement membrane (BM) via degradation of extra-
cellular matrix and BM components. These enzymes are
presented in central and peripheral nervous system. They
are considered to be involved in the pathogenesis of several
neurological diseases, including amyotrophic lateral scle-
rosis (ALS). ALS is a motor neuron disease, leading to
muscle atrophy, paralysis and death within 3–5 years from
diagnosis. Currently, there is no treatment that can sub-
stantially prolong life of ALS patients. Despite the fact that
MMPs are not specific for ALS, there is also strong evi-
dence that these enzymes are involved in the pathology of
ALS. MMPs are able to exert direct neurotoxic effects, or
may cause cell death by degrading matrix proteins. The
objective of this paper is to provide an updated and com-
prehensive review concerning the role of MMPs and their
tissue inhibitors (TIMPs) in the pathology of ALS with an
emphasis on the significance of MMP-2 and MMP-9 as
well as their tissue inhibitors as potential biomarkers of
ALS. Numerous hypotheses have been proposed regarding
the role of selected MMPs and TIMPs in ALS pathogen-
esis. Moreover, selective MMPs’ inhibitors might be
potential targets for therapeutic strategies for patients with
ALS. However, future investigations are necessary before
some of those non-specific for ALS enzymes could finally
be used as biomarkers of this disease.
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Amyotrophic lateral sclerosis (ALS): general
characteristics
Amyotrophic lateral sclerosis (ALS), often referred as a
‘‘Lou Gehrig’s disease’’, is a neurological disorder char-
acterized by degeneration of the lower (LMN) and upper
motor neurons (UMN) in the brain, brainstem and spinal
cord (Garbuzova-Davis et al. 2011; Chiò et al. 2013;
Benkler et al. 2010). ALS is the heterogeneous group of the
most common and most severe form of motor neuron
diseases (MND). This neurodegenerative disorder leads to
a rapid progressive muscular weakness, respiratory failure,
and death within a few years from the diagnosis (Rowland
and Shneider 2001; Garbuzova-Davis et al. 2011). Patients
with exclusive UMN lesion, such as primary lateral scle-
rosis (PLS), as well as patients with sporadic and hereditary
LMN diseases have a more favorable prognosis (Strong
and Gordon 2005; van den Berg-Vos et al. 2003; Süssmuth
et al. 2010).
ALS was classified as sporadic (sALS) and familial
(fALS) disease. Genetically linked fALS accounts for only
5–10 % of cases, among those 20 % present with missense
mutations in the Cu/Zn superoxide dismutase (SOD1) gene
(Rosen 1993). Moreover, hexanucleotide repeat expansions
in C9ORF72 gene, mutations in TAR DNA-binding protein
(TARDBP), mutations in the genes for fused in sarcoma
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(FUS), expanded ataxin 2 (ATXN2) repeats, variants of
angiogenin (ANG) and polymorphisms within axon guid-
ance pathway genes might be also linked with ALS
(Benkler et al. 2010; He et al. 2013; van Es et al. 2011;
Ross et al. 2011; O’Dowd et al. 2012; Duleep and Shefner
2013). Both forms of ALS (sporadic and familial) are
pathologically and clinically similar, which may suggest a
similar final pathway of neurodegeneration, however, the
sporadic ALS generally develops several years later than
fALS (Strong and Gordon 2005; Valdmanis and Rouleau
2008; Cozzolino et al. 2008).
The results of the incidence and prevalence studies are
different due to variations in population demographics,
environmental factors exposure and genetic predisposition
(Chiò et al. 2013). The incidence of ALS might be
underestimated, because the majority of these patients have
only a life expectancy of 3–5 years. In Europe, the median
incidence rate of ALS was 2.08/100.000 population, cor-
responding to an estimated 15.355 cases. The incidence of
ALS is lower among African, Asian and Hispanic ethnic-
ities than among Caucasians (Cronin et al. 2007). More-
over, an estimated uniform prevalence of ALS in Western
countries was 50–100 times higher than elsewhere in the
world (Chiò et al. 2013; Cronin et al. 2007; Wijesekera and
Leigh 2009; Benkler et al. 2010). In addition, the incidence
of ALS increases with age. This disease is the most com-
mon between 45 and 65 years. It is suggested that the
overall incidence of ALS will increase in the future as the
world population ages (Chiò et al. 2013; Wijesekera and
Leigh 2009; Benkler et al. 2010). The authors calculated
that of 60 million people living in the United Kingdom
more than 100,000 people will die from ALS (Ludolph
2006). Therefore, novel approaches for early diagnosis and
especially for the treatment of ALS patients are necessary.
ALS is extremely incapacitating disease. The main signs
and symptoms of ALS are progressive loss of speech, facial
expression, swallowing, gesture, eye movements and in the
in latest stages—a complete loss of efferent contact to the
outside world (Sejvar et al. 2005; Ludolph 2006). The
majority of patients die because of respiratory failure
within 3–5 years of symptom onset. Only 5–10 % of
patients survive beyond 10 years (Chiò et al. 2009; Benkler
et al. 2010; Winter and Birnberg 2003). However, in the
extremely low percentages of cases the survival of ALS
patients might be even longer after diagnosis (Winter and
Birnberg 2003).
The pathogenesis of ALS is still poorly understood,
however, numerous hypotheses have been proposed. ALS is
a multifactorial and multisystemic disease. Various mecha-
nisms are suggested, including: oxidative stress damage,
protein misfolding and aggregation, mitochondrial mal-
function, neurofilament accumulation, defective axonal
transport, increased glutamate excitotoxicity,
neuroinflammation, dysfunction of cell signaling pathways
and deficits in neurotrophic factors (Garbuzova-Davis et al.
2011; Wijesekera and Leigh 2009; Cozzolino et al. 2008).
Some authors indicated that the impairment of the blood–
brain barrier (BBB) or blood–spinal cord barrier (BSCB),
might lead to the motor neuron damage as a potential path-
ogenic mechanism in ALS. Moreover, these barriers are very
important in the maintenance of the central nervous system
(CNS) homeostasis by regulating the molecules exchange
between the peripheral blood and the CNS as well as via
protecting the CNS from fluctuations in plasma composition
(Garbuzova-Davis et al. 2008; Nicaise et al. 2009). Many
factors might play a role in the BBB/BSCB disruption,
including cellular components, transport systems, tight
junction, free radial, cell interaction as well as cytokines and
MMPs (Garbuzova-Davis et al. 2011).
Matrix metalloproteinases in neurological disorders
Matrix metalloproteinases (MMPs) represent a multigene
group of zinc-dependent proteases, capable of degrading of
wide range of substrates, including BM and ECM com-
ponents (Nagase et al. 2006; Brew and Nagase 2010;
Lambert et al. 2004; Morrison et al. 2009; Romi et al.
2012). Therefore, the main function of these proteolytic
enzymes is ECM remodeling and regulation of the cell–cell
and cell–matrix interactions (Murphy and Nagase 2008).
The 26 members of MMPs family were subdivided, based
on their structure and function, into five groups: colla-
genases (MMP-1, -8, -13), gelatinases (MMP-2, -9), ma-
trilysins (MMP-7), stromelysins (MMP-3, -10) and
membrane-type MMPs (e.g., MT-MMP-1) (Table 1) (Bode
et al. 1999; Nagase et al. 2006; Brew and Nagase 2010;
Lambert et al. 2004). MMPs are produced by leukocytes,
macrophages, fibroblasts, endothelial cells, as well as by
astroglia, microglia and neurons (Nagase et al. 2006; As-
ahina et al. 2001; Forsyth et al. 1999). These proteases are
synthesized with a 20 amino acid residue signal peptide
and secreted as pro-proteinases (latent proenzymes, pro-
MMPs), which require activation via cleavage of propep-
tide domain of the molecule (Bode et al. 1999; Romi et al.
2012). The MMPs activity is very low in the normal
steady-state tissues and the majority of the MMPs are
activated by other MMPs or serine proteinases outside the
cell (Lambert et al. 2004; Egeblad and Werb 2002). The
activity of these enzymes is regulated in multistep process
at transcriptional, post-transcriptional and post-transla-
tional levels as well as via growth factors, inflammatory
cytokines, hormones and cell–cell interactions (Lambert
et al. 2004). The active MMPs are inhibited by their
endogenous inhibitors, e.g. by a2-macroglobulin, throm-
bospondin-2 or RECK (reversion-inducing cysteine-rich
protein with kazal motifs)—the membrane-bound inhibitor
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of MMPs (Egeblad and Werb 2002). Among all MMPs
inhibitors, tissue inhibitors of metalloproteinases (TIMPs)
play a crucial role in the regulation of proteolytic activity
of MMPs. TIMPs are the structurally related family of
endogenous inhibitors that includes four members. TIMP-3
is bound to ECM, whereas TIMP-1, -2, and -4 are secreted
in the soluble form (Bode et al. 1999; Ramnath and Cre-
aven 2004). The TIMPs molecule consists of 184–194
amino acids with two structural and functional domains:
N-terminal and C-terminal. N-terminal domain interacts
with the enzyme catalytic domain, while C-terminal region
with pro-forms of MMP-2 and MMP-9 to stabilize this
complex (Ramnath and Creaven 2004). TIMPs inhibit the
proteolytic activity of MMPs in a 1:1 molar stoichiometry,
although not with the same efficiency, thus TIMP-1 is the
most effective inhibitor for MMP-1, MMP-3, MMP-7 and
MMP-9; TIMP-2 for MMP-2; TIMP-3 for MMP-2 and
MMP-9, whereas TIMP-4 reduces the activity of MMP-2
and MT1-MMP (Bourboulia and Stetler-Stevenson 2010;
Nagase et al. 2006; Brew and Nagase 2010; Lambert et al.
2004; Ramnath and Creaven 2004).
MMPs play an important role in tissue remodeling,
including tissue regeneration, wound healing, bone growth
and remodeling, regulation of organ development, such as
muscle and nerves (Bourboulia and Stetler-Stevenson
2010). These proteases are also able to regulate cellular
functions, including cell signaling, survival and angiogen-
esis. Moreover, MMPs might modulate the inflammation
process, macrophage infiltration and axonal growth cone
extension. TIMPs have mainly an inhibitory role, although
they can also act as growth-like factors as well as anti-
angiogenic agents (Brew and Nagase 2010; Bourboulia and
Stetler-Stevenson 2010).
The imbalance between degrading matrix MMPs and
their inhibitors turnover of ECM in all solid organs may
play a role in the development of several pathological
conditions, including rheumatoid arthritis, autoimmune
disorders, chronic ulcerations, tumor growth as well as
Table 1 The classification of
matrix metalloproteinases
(MMPs) and their tissue
inhibitors (TIMPs)
Group MMPs/TIMPs Substrates/efficiencies
Collagenases MMP-1 (collagenase 1) Collagen type I, II, III, V, VII, VIII, X,
gelatine, IL-1b, MMP-2, MMP-9,
fibronectin
MMP-8 (collagenase 2)
MMP-13 (collagenase 3)
MMP-18 (collagenase 4)
Gelatinases MMP-2 (gelatinase A) Collagen type I, IV, V, VII, X, gelatin,
elastin, lamininMMP-9 (gelatinase B)
Matrilysins MMP-7 Collagen type IV, glycoproteins, gelatin
MMP-11
MMP-26
Stromelysins MMP-3 (stromelysin 1) Proteoglycans, fibronectin, laminin, elastin,
gelatin, vitronectin, plasminogen,
fibrinogen, fibrin, collagen type III, IV, V,
antithrombin III
MMP-10 (stromelysin 2)
Membrane-type MMPs MMP-14 (MT1-MMP) Collagen type I, II, III, gelatin, elastin,
laminin, fibronectin, fibrin, proMMP-2, -13Transmembrane-type MMPs MMP-15 (MT2-MMP)
GPI-anchored MMPs MMP-16 (MT3-MMP)
MMP-24 (MT5-MMP)
MMP-17 (MT4-MMP)
MMP-25 (MT6-MMP)
Other MMPs MMP-12 Amelogenin, aggrecan, elastin
MMP-19
MMP-20
MMP-21
MMP-23
MMP-27
MMP-28
TIMPs TIMP-1 MMP-1, MMP-3, MMP-7, MMP-9
TIMP-2 MMP-2
TIMP-3 MMP-2, MMP-9
TIMP-4 MMP-2, MT1-MMP
MMPs and TIMPs in ALS 1389
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various disorders of the CNS, including cerebral stroke,
Alzheimer’s disease (AD), multiple sclerosis (MS) and
ALS (Brew and Nagase 2010; Bourboulia and Stetler-
Stevenson 2010; Demir et al. 2012; Stomrud et al. 2010;
Rosenberg 2009; Mroczko et al. 2013).
Biomarkers in the amyotrophic lateral sclerosis (ALS)
diagnosis
The diagnosis of ALS patients is based on the medical
history and progressive UNM and LMN deficits. The
electromyography is used to diagnose conditions that
may mimic ALS, while MRI of brain may indicate non-
specific changes in the bilateral signal within the corti-
cospinal tracts (Gordon 2013; Duleep and Shefner 2013).
Currently, there are no generally accepted biomark-
ers with proven reliability as a measure of disease bur-
den in ALS, which is a major problem in routine
practice (Cudkowicz and Swash 2010). Moreover, all the
biomarkers and candidates presented by authors do not
seem to be specific for ALS, but rather reflect neuro-
degeneration. Therefore, novel biomarkers for ALS may
simplify as well as accelerate the investigative process,
leading to earlier implementation of available therapies
(Ganesalingam et al. 2011).
The potential ALS biomarkers should identify the pre-
symptomatic patients and monitor the progression and
regional involvement in ALS. These criteria will allow for
the identification of effective drugs and planning of a long-
term therapy (Shoesmith et al. 2007; Winhammar et al.
2005). What is important are standardized sample pro-
cessing, methods and protocols, storage as well as spe-
cialized laboratories, which are necessary to define highly
specific and sensitive biomarkers for ALS. Moreover, it
should demonstrate clinical utility in prospective studies
and must be validated in a separate set of samples (Bowser
and Lacomis 2009). A single biomarker is usually unlikely
to fulfill all these criteria; therefore, current efforts need to
be focused on generating a panel of biomarkers, useful in
the combination with clinical parameters to more accurate
diagnosis of the disease (Ganesalingam et al. 2011).
So far, several potential biomarkers have been evaluated
in CSF of patients with ALS. The CSF analysis is still one
of the basic laboratory tools, especially in the evaluation of
BCSFB (Tarasiuk et al. 2012; Rothstein 2009). Süssmuth
et al. (2010) assessed the CSF concentrations of total tau
protein, S100 beta (S100b), and sCD14 (soluble cluster of
differentiation 14), which indicated markers of neurode-
generation, astroglial activation, and neuroinflammation
processes, respectively. The authors demonstrated that total
tau levels in CSF were significantly elevated in ALS
compared to controls, suggesting that the increased CSF
total tau concentrations may reflect the degeneration
process within large caliber axons (Süssmuth et al. 2010).
The CSF concentrations of S100 beta and sCD14 correlated
with the survival of patients with ALS. Combined mea-
surement of all these markers might have prognostic value.
The authors concluded that the assessment of these markers
could be useful for clinical trials and in the future even in
clinical practice (Süssmuth et al. 2010).
Cytoskeletal modification within neurofilament proteins
was also shown in ALS. During axonal injury, cytoskeletal
proteins are released into the interstitial fluid and accu-
mulated in the CSF and blood. Tortelli et al. (2012) using
ELISA method revealed that the concentrations of neuro-
filament light chain (NFL) in CSF were significantly higher
in ALS cases than in neurological controls. In addition, the
NFL levels discriminated between ALS patients and neu-
rological controls, with a sensitivity of 78.4 % and speci-
ficity of 72.5 %. The authors demonstrated that in ALS
patients, CSF NFL concentrations negatively correlated
with the diagnosis delay and positively correlated with the
disease progression rate. These findings confirmed that
elevated CSF NFL concentrations might reflect the burden
of neurodegeneration, whereas the significant correlations
between NFL in CSF concentrations and disease progres-
sion suggested that NFL could be a useful marker of dis-
ease activity and progression (Tortelli et al. 2012). In
patients with ALS, the prognostic and diagnostic values of
the CSF levels of phosphorylated neurofilament heavy
chain and complement C3 (pNFH/C3) were also confirmed
(Ganesalingam and Bowser 2010). Puentes et al. (2013)
revealed that antibody levels to neurofilament (NF) pro-
teins in plasma were significantly higher in ALS individ-
uals compared to healthy controls. The authors suggested
that NF antibody concentrations in plasma could be used as
biomarker for ALS (Puentes et al. 2013). The changes of
presented biomarkers levels were not specific only for
ALS, but their levels also changed in other neurodegen-
erative diseases (Cudkowicz and Swash 2010).
In summary, there is an increasing data indicating that
biological markers of pathological processes, involved in
the pathogenesis of ALS, reflecting oxidative stress, neu-
rotransmission or neuroprotection, might play a role as
markers of diagnosis and prognosis of ALS patients (Kiaei
et al. 2007).
Matrix metalloproteinases (MMPs) and their tissue
inhibitors (TIMPs) in the amyotrophic lateral sclerosis
(ALS)
In CNS metalloproteinases are enzymes expressed by
neurons, astrocytes and microglia. They are able to deter-
minate the integrity of the basement membrane via deg-
radation of ECM and BM components (Gasche et al. 2006).
The major components of BM, such as laminin and
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collagen type IV provide a mechanical support to the
endothelium and limit passage of macromolecules through
the BBB/BSCB, thus BM surrounded by the endothelial
cells is part of the BBB/BSCB. Therefore, MMPs are
thought to be an essential enzymes that might determinate
the BBB/BSCB maintenance. In pathological conditions
within CNS, the main function of MMPs is remodeling
during tissue repair and development. These enzymes are
also involved in increase in the BBB/BSCB permeability
during inflammatory processes via facilitating the migra-
tion of cellular and non-cellular agents. It was shown that
MMP-3 and MMP-9 may increase BBB/BSCB perme-
ability due to activation of microglia and indirectly via
stimulation cytokines’ secretion and free radicals (Nuttall
et al. 2007; Woo et al. 2008). MMPs are able to converted
proinflammatory cytokines, such as interleukin 1 beta (IL-
1b) into its biologically active form. MMP-2 activated IL-
1b in 24 h, MMP-3 in 1 h, while MMP-9 process pro-IL-
1b into its active form only in a few minutes. Therefore,
MMPs are enzymes that may promote inflammatory pro-
cesses, and indirectly affect BBB permeability (Romi et al.
2012; Pozzi and Zent 2009; Gasche et al. 2006; Candela-
rio-Jalil et al. 2009; Taraboletti et al. 2002; Opdenakker
et al. 2001). In addition, the immune cells migrated from
the peripheral blood, such as neutrophils during inflam-
matory process may release the MMPs that intensify the
inflammatory reaction and damage of BBB/BSCB (Gar-
buzova-Davis et al. 2011). Elevated activity of MMP-2 and
MMP-9 leads to increase in the vessel permeability (Fang
et al. 2010). Moreover, MMPs may also modulate signaling
molecules, cleave circulating and cell surface proteins, as
well as interfere with cellular function (Candelario-Jalil
et al. 2009; Sternlicht and Werb 2001). These enzymes are
also able to degrade adhesion molecules, including the
vascular endothelial cadherin.
MMPs play a potential role in the pathogenesis of var-
ious diseases of the CNS via common pathophysiological
processes, such as BBB disruption, oxidative stress,
remodeling of the ECM as well as inflammation (Gasche
et al. 2006). However, the mechanism of neuronal death
caused by the MMPs, especially MMP-9 is still poorly
understood. These enzymes might involve in the disruption
of the neuronal ECM interaction, leading to cell death (Gu
et al. 2002). Kiaei et al. (2007) indicated that MMP-9 plays
a role in the pathogenesis of ALS. In this study, the authors
crossed G93A SOD1 mice with MMP-9 ‘‘knockout’’ mice
and showed increased immunoreactivity and activity of
MMP-9 in spinal cord tissues of transgenic mouse model of
ALS (G93A SOD1 mice). Moreover, Kaplan et al. (2014)
revealed that reduction of MMP-9 function might delay
muscle denervation and prolong survival in ALS model
mice expressing mutant SOD1. The authors suggested that
MMP-9 triggers degeneration and could be a marker for
vulnerable fast motor neurons, thus this enzyme might be a
candidate for therapeutic target for ALS (Kaplan et al.
2014). In addition, elevated levels of MMP-9 were
observed in the spinal cord homogenates of G93A SOD1
mice in early stage of ALS, while the lack of MMP-9
improved survival. Similar results were presented by other
authors (Dewil et al. 2005). Moreover, Soon et al. (2010)
indicated that circulating MMP-9 level increased through-
out the course of disease progression in mice. The mech-
anism for MMP-9 neurotoxicity in ALS may be due to
upregulating neuronal TNF-a (tumor necrosis factor alfa)
expression and activation; MMP-9 was involved in cleav-
age of TNF-a from its membrane-bound form via its
receptor (TNF-R1), leading to cells’ apoptosis. The authors
concluded that MMP-9 contributes to the motor neuron cell
death via pro-inflammatory cytokines, suggesting the
potential role of MMP-9 in the ALS (Kiaei et al. 2007).
The significance of MMP-9 in the pathogenesis of ALS
was also confirmed in the brain and spinal cord tissue of
ALS patients, using immunohistochemistry and zymogra-
phy methods (Lim et al. 1996). Immunohistochemical
studies indicated the presence of MMP-2 in astrocytes and
MMP-9 in pyramidal neurons in the motor cortex and
motor neurons in the spinal cord of ALS patients. The
highest MMP-9 activity in ALS was observed in the motor
cortex and thoracic and lumbar cord specimens. Statisti-
cally significant increases in MMP-9 activity were found in
ALS frontal and occipital cortices when compared with
control specimens, while MMP-2 activity was significantly
lower in the ALS motor cortex. The authors concluded that
abnormally high amount of MMP-9 and its possible release
at the synapse may impair the structural integrity of the
surrounding matrix, contributing to the ALS pathogenesis
(Lim et al. 1996).
ALS is the most common form of motor neuron disease.
It was observed that other organs, including skin, may be
also affected. Therefore, some authors assessed a possible
link between neurodegeneration and the skin pathology in
ALS by the determination of selected MMPs (Fang et al.
2009). Fang et al. (2010) revealed elevated MMP-9 con-
centrations in the skin of the transgenic G93A SOD1 mice,
what was in line with increased activity of this enzyme in
skin tissue homogenate as well as increased levels of
MMP-9 mRNA, measured by real-time PCR (RT-PCR).
However, no statistical differences were found in MMP-2
levels. The discrepancy between MMP-2 and MMP-9
might be caused by the regulation of MMP gene expres-
sion—different responsiveness to activating stimuli (Vin-
centi and Brinckerhoff 2007). Moreover, MMP-9 is an
enzyme that contain a TATA box sequence and an acti-
vator protein-I (AP-I) site in their promoter regions, which
are associated with a high responsiveness to stimuli,
including oxidative stress and cytokines. In the promoter
MMPs and TIMPs in ALS 1391
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region of MMP-2 there is a lack of both the TATA box
sequence and the AP-I site (Yan and Boyd 2007; Mancini
and Di Battista 2006). In addition, the oxidative stress and
microglial-derived cytokines contribute to the elevation of
both MMPs levels, especially in later stages of disease.
These findings suggested that MMP-9 play a role in neu-
rodegeneration as well as in the skin changes in ALS and
may be a possible factor linking distant aspects of disease
pathology. However, whether the skin may offer an easily
source of biomarkers that could allow monitoring specific
aspects of ALS pathology needs to be clarified in future
studies. The authors also indicated that the MMP-9 con-
centrations were significantly higher in skin tissue
homogenates of ALS patients compared to control group
(Fang et al. 2009). No significant difference of MMP-2
concentrations in skin between ALS patients and control
group was found. These findings confirmed a general
upregulation of MMP-9 levels in ALS pathology, inde-
pendent on the stage of disease or clinical subtypes (Fang
et al. 2009).
Interestingly, the variations in the MMPs immunoreac-
tivity have been also demonstrated in muscle biopsies from
ALS patients. In normal muscle, the immunoreactivity of
MMP-2, MMP-7 and MMP-9 was observed at neuromus-
cular junctions, in vessels and nerve branches, while MMP-
9 expression was more intense in atrophic muscle of ALS
patients compared to normal muscle. The authors sug-
gested that distinct expression patterns of MMPs reflects
different stages of muscle denervation atrophy and con-
firmed that MMP-9 may contribute to the pathogenesis of
ALS around atrophic myofibers (Schoser and Blottner
1999).
ALS also affects the stromal compartment of bone
marrow, thus non-neuronal neighboring cells might be
involved in the pathological neuronal loss. Bossolasco
et al. (2010) indicated normal hematopoietic biological
properties in ALS patients, however, an atypical behavior
and impaired stem cells capabilities have been found in the
mesenchymal compartment (MSCs). Quantitative deter-
mination of mRNA expression in MSCs revealed that in
ALS patients the MMP-9 expression was significantly
higher than in healthy controls, suggesting that increase of
MMP-9 mRNA could reflect an enhanced production of
MMP-9, which trigger the transcription of collagen to
compensate its reduction in protein level (Bossolasco et al.
2010). In addition, the authors using ELISA method
showed higher MMP-9 concentrations in MSCs of ALS
patients as compared to healthy group. However, the sig-
nificant decrease of MMP-1, MMP-2, MMP-3, and TIMP-2
concentrations in MSCs of patients with ALS has been
found in comparison to healthy controls, whereas TIMP-1
levels showed no significant variation in comparison to
control group (Bossolasco et al. 2010). Moreover,
zymography analysis of MMP-9 activity revealed no sig-
nificant differences between healthy subjects and ALS
patients, what authors explained by variability between
lysates and/or restricted number of available samples.
These findings confirmed biological alterations of selected
MMPs and their tissue inhibitors in MSC compartment in
ALS and proposed to add the bone marrow to the different
districts already reported as altered in the pathology of this
disease (Bossolasco et al. 2010).
The significance of MMP-9 in ALS may be explained by
several mechanisms, such as altered release of MMP-9 at
the synapses, leading to degeneration of the structural
integrity of the surrounding matrix. MMP-9 is able to
cleave neuropeptide—substance P (SP), which acts as a
neurotransmitter in the spinal cord (Lim et al. 1996). In
addition, serine proteinases or superoxide radicals could
promote the conversion of non-active form of MMP-9 to its
active form (Lim et al. 1996; Kim et al. 2003). The MMP-9
activity might be also affected by functional genetic vari-
ants of the MMP-9 gene. The concentrations and activity of
MMP-9 are influenced by the polymorphism of the MMP-9
gene (Zawiślak et al. 2009). The authors failed to confirm
that the polymorphism –1562 C/T of the MMP-9 gene is
associated with the risk of sporadic ALS in patients.
Therefore, abnormal amount of MMP-9 in ALS could be a
result of uncontrolled MMP-9 release due to non-specific
atrophy of muscles and nerves in the course of the disease
or other non-genetic mechanisms, such as modification of
transcription by various cytokines, activation of latent
MMPs as well as inhibition of MMP-9 by their tissue
inhibitors (Montaner et al. 2003; Zawiślak et al. 2009).
The changes in the selected MMPs and their tissue
inhibitors levels were previously demonstrated in the CSF
and blood of ALS patients (Niebroj-Dobosz et al. 2010;
Beuche et al. 2000). The authors showed by ELISA method
that in the CSF of ALS patients the concentrations of MT-
MMP-1, MMP-2 and TIMP-1 were higher than in healthy
controls (Niebroj-Dobosz et al. 2010). In addition, Lorenzl
et al. (2003a) indicated the significant increase of CSF
TIMP-1 concentrations in ALS patients compared to con-
trol group. The elevated levels of selected MMPs and
TIMPs in CSF could be related with activation of the
immune system, while higher concentrations of MT-MMP-
1 and MMP-2 in CSF may be also involved in increased
permeability of the BBB, thus the breakdown of the
BCSFB appears in about 20–46 % of the ALS patients
(Niebroj-Dobosz et al. 2010). Moreover, the elevation of
MMP-2 and MT-MMP-1 levels might be result of imbal-
ance between MMP-2 and their natural inhibitor—TIMP-2.
The study also revealed that the MMP-9 concentrations in
ALS patients were lower than in control group and had a
tendency to further decrease with more advanced clinical
status. However, no correlation between the MMP-9 levels
1392 M. Łukaszewicz-Zając et al.
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in CSF and the duration of the disease was presented. The
TIMP-2 concentrations did not differ between both ana-
lyzed group (ALS patients vs. healthy controls) (Niebroj-
Dobosz et al. 2010). Decreased MMP-9 levels in CSF
might be explained by low penetration of this enzyme
through the BCSFB as well as by its higher inhibition by
increased TIMP-1 level and/or its increased intrathecal
degradation and physical clearance. Other authors assessed
the CSF MMP-9 levels in patients with ALS as well as in
subjects with inflammatory disease, such viral meningo-
encephalitis or bacterial meningitis. They indicated that
MMP-9 concentrations were not elevated in CSF of ALS
patients, in contrast to those with inflammatory diseases
(Beuche et al. 2000). Opposite findings were presented by
Fang et al. (2009) who assessed that in ALS patients the
MMP-9 concentrations in CSF were significantly higher
than in healthy controls and increased with a rapid pro-
gressive course of disease, while no significant differences
of MMP-2 concentrations were assessed in the CSF of ALS
patients as compared to controls. The authors suggested
that elevated concentrations of MMP-9 in CSF were
associated with extensive neuroaxonal degeneration, rapid
progression of disease and poorer ALS patients’ survival
(Fang et al. 2009). The discrepancy between MMP-9 levels
in the CSF sample might be explained by different number
of samples, sample processing, measurement methods and
protocols. Therefore, the role of changed CSF MMPs/
TIMPs levels in the pathogenesis of ALS is still not clear
enough to use these enzymes as CSF biomarkers of ALS
(Niebroj-Dobosz et al. 2010).
Table 2 The summary of the significance of selected matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in the amyotrophic
lateral sclerosis (ALS)
Source MMPs/TIMPs Methods References
1. Spinal cord of transgenic mouse
model
:MMP-9 Immunohistochemistry
(immunoreactivity) zymography
(activity)
Kiaei et al. (2007)
2. Spinal cord of ALS patients :MMP-9
;MMP-2
Immunohistochemistry
(immunoreactivity) zymography
(activity)
Lim et al. (1996)
3. Spinal cord and skin of transgenic
mouse model
:MMP-9
$MMP-2
ELISA (concentration) gel
zymography (activity) RT-PCR
(mRNA level)
Fang et al. (2010)
4. Skin tissue of ALS patients :MMP-9
$MMP-2
ELISA (concentration) Fang et al. (2009)
5. Stromal compartment of bone
marrow of ALS patients
:MMP-9
:MMP-9,; MMP-1, -2, -3,
TIMP-2, $TIMP-1
$MMP-9
RT-PCR (mRNA level) ELISA
(concentration) zymography
(activity)
Bossolasco et al. (2010)
6. CSF of ALS patients :MT-MMP-1, MMP-2 and
TIMP-1
;MMP-9, $TIMP-2
:MMP-2, ;MMP-9
ELISA (concentration)
zymography (activity)
Niebroj-Dobosz et al. (2010)
7. CSF of ALS patients :TIMP-1 ELISA (concentration) Lorenzl et al. (2003a)
8. CSF of ALS patients $MMP-9 ELISA (concentration) Beuche et al. (2000)
9. CSF of ALS patients :MMP-9
$MMP-2
ELISA (concentration) Fang et al. (2009)
10. Serum of ALS patients :pro-MMP-9, MMP-9 ELISA (concentration)
zymography (activity) Western
blot
Demestre et al. (2005)
11. Serum of ALS patients :MMP-9 ELISA (concentration) Beuche et al. (2000)
12. Serum of ALS patients $MMP-9, MMP-2 ELISA (concentration) Fang et al. (2009)
13. Serum of ALS patients :MT-MMP-2, MMP-2,
MMP-9, TIMP-1
$TIMP-2
:MMP-2, MMP-9
ELISA (concentration)
zymography (activity)
Niebroj-Dobosz et al. (2010)
14. Plasma of ALS patients $MMP-9 ELISA (concentration) Lorenzl et al. (2003b)
: Increased, ; decreased, $ no significant changes
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CSF is slow circulating fluid and its characteristics differ
by location, the concentrations of metabolites at differing
times of day as well as by the effects of diet, alcohol, and
various types of drugs. Although the CSF analysis is still
one of the basic laboratory tools, lumbar puncture is con-
sidered by many neurologists to be unnecessary in the
clinical diagnosis of ALS (Cudkowicz and Swash 2010).
Currently, there are no blood markers that can facilitate
diagnosis or assessment of prognosis in ALS. Therefore,
detection of selected biochemical biomarkers not only in
the CSF, but also in the blood of ALS patients, using easy
to perform and sensitive method like ELISA is necessary
during the diagnosis and prognosis course of ALS patients
(Tables 2, 3).
Demestre et al. (2005) indicated that serum pro-form of
MMP-9 concentrations were significantly higher in ALS
patients than in healthy controls and significantly higher in
sera from Guillain–Barre syndrome (GBS) patients com-
pared with either ALS patients or healthy controls.
Whereas for active MMP-9 the difference was significant
for both ALS and GBS versus healthy controls, and was
similar between ALS and GBS groups (Demestre et al.
2005). Similar results were found by the Beuche et al.
(2000) who also revealed significantly elevated MMP-9
concentrations in the sera of ALS patients than in healthy
controls, although the levels of MMP-9 increased up to
levels as high as those of viral meningoencephalitis or
bacterial meningitis patients and remained elevated during
long-term observation of ALS patients (Beuche et al.
2000). The authors suggested that in the absence of an
inflammatory response, the increase of MMP-9 in serum of
ALS patients might be caused by upregulation of MMP-9
in denervated muscles or in degenerating peripheral nerves
causing motor neuron loss (Beuche et al. 2000). In addi-
tion, Fang et al. (2009) indicated higher MMP-9 levels in
the serum of ALS patients in comparison to healthy con-
trols; however, these differences did not reach statistical
significance, likewise the serum MMP-2 levels. The
authors also failed to show any significant correlation
between the analyzed MMPs and clinical subtype or dis-
ease progression over follow-up (Fang et al. 2009). On the
contrary, Niebroj-Dobosz et al. (2010) showed that MT-
MMP-1, MMP-2, MMP-9 and TIMP-1 concentrations in
the serum of ALS patients were significantly elevated. The
serum MMP-2 and MMP-9 concentrations differed signif-
icantly between the mild and severe ALS subgroup, while
TIMP-2 levels were in the normal values in both ALS
subgroups. In addition, in the total ALS group, a correla-
tion between MT-MMP-1, MMP-2, MMP-9 concentrations
and duration of the disease was presented. Similar data
were demonstrated, using zymography, where the activity
of MMP-2 and MMP-9 was higher in serum of ALS
patients compared to control group (Niebroj-Dobosz et al.
2010). Moreover, the biomedical data of Sokolowska et al.
(2009) demonstrated the application of the pattern recog-
nition methods for the assessment of selected MMPs in
Table 3 The role of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) as candidates for the amyotrophic lateral sclerosis
(ALS) biomarkers
References MMPs/TIMPs Potential biomarker of: Source
1 Kiaei et al. (2007) MMP-9
TIMPs
Motor neuron cell death
Survival
Therapeutic strategy for ALS
Spinal cord of transgenic mouse model
2 Soon et al. (2010) MMP-9 Disease progression
Monitoring therapeutic effects in
preclinical trials in ALS
Serum of TgSOD1 G93A low copy
transgenic mice
3 Schoser and Blottner (1999) MMPs Stages of muscle denervation atrophy Muscles of ALS patients
4 Niebroj-Dobosz et al. (2010) MMP-9
MT-MMP-1/MMP-2
MMPs/TIMPs
MMPs
More advanced clinical status
Increased permeability of the BBB
Activation of the immune system
Ongoing degeneration of motor neurons
and muscles
CSF/serum of ALS patients
5 Fang et al. (2009) MMP-9 Extensive neuroaxonal degeneration,
rapid progression of disease and
poorer ALS patients’ survival
Skin tissue/CSF of ALS patients
6 Sokolowska et al. (2009) MMP-2
MT-MMP-1/MMP-9
The evaluation of ALS progress
Distinguishing ALS patients from
healthy population
Serum of ALS patients
7 He et al. (2013) MMP-9 Risk for ALS (polymorphism in the
MMP-9 gene)
Peripheral blood leukocytes of ALS
patients
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serum of patients with ALS using ELISA method. The
authors proved that serum MMP-2 may be a marker for the
evaluation of ALS progress, while serum MT-MMP-1 and
MMP-9 could be useful in distinguishing ALS patients
from healthy population. These findings concluded that the
presented pattern recognition approach for the examination
of the clinical status of ALS allows evaluating the signif-
icance of MMPs as biomarkers in ALS (Sokolowska et al.
2009). ELISA technique was also used to assess the con-
centrations of MMP-2, MMP-9, TIMP-1 and TIMP-2 in the
plasma of patients with ALS (Lorenzl et al. 2003b).
Lorenzl et al. (2003b) demonstrated that plasma concen-
trations of MMP-9 in ALS patients were not statistically
different from controls, while TIMP-1 and TIMP-2 levels
were unchanged. Many authors confirmed that the origin of
variation in the MMPs and TIMP-1 levels in ALS patients
is unclear, thus these enzymes might be derived from
affected nerve axons and/or denervated muscles and may
reflect ongoing degeneration of motor neurons and muscles
and/or could be associated with their remodeling. The
changes in the MMPs levels might be also secondary as a
consequence of the action of oxidative stress (Beuche et al.
2000; Schoser and Blottner 1999). The discrepancies
between the results presented by different authors cause
that it is still not clear whether the analysis of selected
MMPs and their tissue inhibitors in body fluids may be
used as prognostic factor and a potential marker for mon-
itoring treatment of ALS patients (Niebroj-Dobosz et al.
2010).
Conclusion
There is an ongoing discussion whether alterations of
MMPs levels in CSF and blood are beneficial or detri-
mental in ALS. MMPs are non-specific enzymes that
differ in their primary structure, molecular weight, sub-
strate specificity, sensitivity to inhibitors, function, tissue
expression and activity. In the physiological condition in
CNS these enzymes are important regulators of myelin
turnover, cell migration and survival as well as axonal
physiology and synaptic plasticity; however, there is also
strong evidence that MMPs may play detrimental roles
in neurological diseases (Fang et al. 2010). Selected
MMPs are involved in mediation of disruption of BBB
as well as inflammation process via cleaving of various
cytokines (Fang et al. 2009). Elevated MMPs levels may
induce tissue injury via their ability to mediate apoptosis
of neural cells, causing degeneration of neurons. More-
over, MMPs can exert direct neurotoxic effects, or may
cause cell death by degrading matrix proteins. Despite of
the fact that the mechanisms of MMPs/TIMPs changes in
ALS remain unknown and these enzymes are not specific
for ALS, there is strong evidence that MMPs contribute
to ALS pathology and may be targets for future thera-
peutic strategies using selective MMPs’ inhibitors.
Although, there are many technical and clinical limita-
tions in the presented studies, future researches con-
cerning the significance of selected MMPs and their
tissue inhibitors as potential biomarkers for ALS need to
be continued.
Open Access This article is distributed under the terms of the
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Chiò A, Logroscino G, Hardiman O, Swingler R, Mitchell D, Beghi E
et al (2009) Prognostic factors in ALS: a critical review.
Amyotroph Lateral Scler 10:310–323
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